Clinical trials further demonstrate that EPA and DHA supplementation alleviates hepatic steatosis and inflammation while improving insulin sensitivity and reducing cardiovascular risk, key MASLD comorbidities (Banaszak et al. 2024). The gene discussed is INS; the disease is Hepatic steatosis.